Anti‑IL‑20 monoclonal antibody suppresses hepatocellular carcinoma progression

Ding,Wen‑Zhou; Han,Guo‑Yong; Jin,Hui‑Han; Zhan,Chuan‑Fei; Ji,Yuan; Huang,Xin‑Li

doi:10.3892/ol.2018.9402

Anti‑IL‑20 monoclonal antibody suppresses hepatocellular carcinoma progression

Authors:
- Wen‑Zhou Ding
- Guo‑Yong Han
- Hui‑Han Jin
- Chuan‑Fei Zhan
- Yuan Ji
- Xin‑Li Huang
View Affiliations

Affiliations: Department of Hepatobiliary Surgery, Nanjing Medical University Affiliated Wuxi Second Hospital, Wuxi, Jiangsu 214002, P.R. China, Key Laboratory of Living Donor Liver Transplantation, National Health and Family Planning Commission, Department of Liver Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, P.R. China, Department of Hepatobiliary Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu 210008, P.R. China
Published online on: September 5, 2018 https://doi.org/10.3892/ol.2018.9402
Pages: 6156-6162

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Interleukin (IL)‑20 is a member of the IL‑10 family of cytokines, which has been reported to participate in autoimmune inflammatory diseases. However, the potential role of IL‑20 in hepatocellular carcinoma (HCC) progression has not yet been investigated. In the present study, it was observed that IL‑20 mRNA and protein levels were markedly increased in the HCC tissues examined via reverse transcription‑quantitative polymerase chain reaction and immunohistochemical staining. In addition, IL‑20 expression was significantly associated with tumor size, metastasis, TNM stage and poor prognosis in patients with HCC. Mouse recombinant IL‑20 (mIL‑20) enhanced liver cancer cell proliferation, migration and invasion in vitro, while the anti‑IL‑20 monoclonal antibody (mAb) attenuated the effect of mIL‑20, inhibiting cancer cell migration and invasion in vitro and suppressing cell growth in vitro and in vivo. This was detected by Cell Counting Kit‑8, colony formation, Transwell assays and a xenograft tumor nude mouse model. Western blotting revealed that IL‑20 promoted HCC progression through inducing transforming growth factor‑β and matrix metalloproteinase 9 expression and enhancing the phosphorylation of Jun N‑terminal kinase and signal transducer and activator of transcription 3. The results of the present study indicated that IL‑20 promotes HCC development. In addition, anti‑IL‑20 mAb may attenuate the effect of IL‑20 and suppress liver tumorigenesis in vitro and in vivo, indicating that anti‑IL‑20 mAbs may potentially serve as effective therapeutic agents for HCC.

View Figures

View References

1	Venook AP, Papandreou C, Furuse J and de Guevara LL: The incidence and epidemiology of hepatocellular carcinoma: A global and regional perspective. Oncologist. 154 Suppl 4:S5–S13. 2010. View Article : Google Scholar
2	Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
3	Sabat R: IL-10 family of cytokines. Cytokine Growth Factor Rev. 215:315–324. 2010. View Article : Google Scholar
4	Rutz S, Wang X and Ouyang W: The IL-20 subfamily of cytokines-from host defence to tissue homeostasis. Nat Rev Immunol. 14:783–795. 2014. View Article : Google Scholar : PubMed/NCBI
5	Wegenka UM: IL-20: Biological functions mediated through two types of receptor complexes. Cytokine Growth Factor Rev. 21:353–363. 2010. View Article : Google Scholar : PubMed/NCBI
6	Blumberg H, Conklin D, Xu WF, Grossmann A, Brender T, Carollo S, Eagan M, Foster D, Haldeman BA, Hammond A, et al: Interleukin 2: Discovery, receptor identification, and role in epidermal function. Cell. 104:9–19. 2001. View Article : Google Scholar : PubMed/NCBI
7	Wei CC, Hsu YH, Li HH, Wang YC, Hsieh MY, Chen WY, Hsing CH and Chang MS: IL-20: Biological functions and clinical implications. J Biomed Sci. 13:601–612. 2006. View Article : Google Scholar : PubMed/NCBI
8	Gedebjerg A, Johansen C, Kragballe K and Iversen L: IL-20, IL-21 and p40: Potential biomarkers of treatment response for ustekinumab. Acta Derm Venereol. 93:150–155. 2013. View Article : Google Scholar : PubMed/NCBI
9	Hsu YH, Hsing CH, Li CF, Chan CH, Chang MC, Yan JJ and Chang MS: Anti-IL-20 monoclonal antibody suppresses breast cancer progression and bone osteolysis in murinemodels. J Immunol. 188:1981–1991. 2012. View Article : Google Scholar : PubMed/NCBI
10	Lee SJ, Cho SC, Lee EJ, Kim S, Lee SB, Lim JH, Choi YH, Kim WJ and Moon SK: Interleukin-20 promotes migration of bladder cancer cells through extracellular signal-regulated kinase (ERK)-mediated MMP-9 protein expression leading to nuclear factor (NF-κB) activation by inducing the up-regulation of p21(WAF1) protein expression. J Biol Chem. 288:5539–5552. 2013. View Article : Google Scholar : PubMed/NCBI
11	Wegenka UM, Dikopoulos N, Reimann J, Adler G and Wahl C: The murine liver is a potential target organ for IL-19, IL-20 and IL-24: Type I Interferons and LPS regulatethe expression of IL-20R2. J Hepatol. 46:257–265. 2007. View Article : Google Scholar : PubMed/NCBI
12	Chiu YS, Wei CC, Lin YJ, Hsu YH and Chang MS: IL-20 and IL-20R1 antibodies protect against liver fibrosis. Hepatology. 60:1003–10014. 2014. View Article : Google Scholar : PubMed/NCBI
13	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
14	Zhang Z, Zhang Y, Sun XX, Ma X and Chen ZN: Chen, microRNA-146a inhibits cancer metastasis by downregulating VEGF through dual pathways in hepatocellular carcinoma. Mol Cancer. 14:52015. View Article : Google Scholar : PubMed/NCBI
15	Ji Y, Fan J, Zhang L, Tan Y, Zhou J, Zeng H, Ren Z and Xu J: Analysis of signal pathway activation in hepatocellular carcinoma: Association with clinical outcomes to sorafenib in Chinese patients. J Clin Oncol. 20:272009.
16	Liu J, Chen S, Wang W, Ning BF, Chen F, Shen W, Ding J, Chen W, Xie WF and Zhang X: Cancer-associated fibroblasts promote hepatocellular carcinoma metastasis through chemokine-activated hedgehog and TGF-β pathways. Cancer Lett. 379:49–59. 2016. View Article : Google Scholar : PubMed/NCBI
17	Lu L, Zhang Q, Wu K, Chen X, Zheng Y, Zhu C and Wu J: Hepatitis C virus NS3 protein enhances cancer cell invasion by activating matrix metalloproteinase-9 and cyclooxygenase-2 through ERK/p38/NF-κB signal cascade. Cancer Lett. 356:470–478. 2015. View Article : Google Scholar : PubMed/NCBI
18	He G, Yu GY, Temkin V, Ogata H, Kuntzen C, Sakurai T, Sieghart W, Peck-Radosavljevic M, Leffert HL and Karin M: Hepatocyte IKKβ/NF-κB inhibits tumor promotion and progression by preventing oxidative stress-driven STAT3 activation. Cancer Cell. 17:286–297. 2010. View Article : Google Scholar : PubMed/NCBI
19	Chang Q, Zhang Y, Beezhold KJ, Bhatia D, Zhao H, Chen J, Castranova V, Shi X and Chen F: Sustained JNK1 activation is associated with altered histone H3 methylations in human liver cancer. J Hepatol. 50:323–333. 2009. View Article : Google Scholar : PubMed/NCBI
20	Hibi M, Lin A, Smeal T, Minden A and Karin M: Identification of an oncoprotein- and UV-responsive protein kinase that binds and potentiates the c-Jun activation domain. Genes Dev. 7:2135–2148. 1993. View Article : Google Scholar : PubMed/NCBI
21	Eferl R, Ricci R, Kenner L, Zenz R, David JP, Rath M and Wagner EF: Liver tumor development: c-Jun antagonizes the proapoptotic activity of p53. Cell. 112:181–7192. 2003. View Article : Google Scholar : PubMed/NCBI
22	Giannelli G, Koudelkova P, Dituri F and Mikulits W: Role of epithelial to mesenchymal transition in hepatocellular carcinoma. J Hepatol. 65:798–808. 2016. View Article : Google Scholar : PubMed/NCBI